For the Inventor, By the Inventor

Enter inventor name

O'Fallon, MO, United States of America

James Robert Blinn

USPTO Granted Patents = 21 (Patent Applications = 19)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 7)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 47(Granted Patents)

Location History:

Lawton, MI (US) (2004)
Brooklyn, NY (US) (2016 - 2017)
O'Fallon, MO (US) (2015 - 2023)

Company Filing History:

Aclaris Therapeutics, Inc.

Confluence Life Sciences, Inc.

Adaris Therapeutics, Inc.

5. 2 out of 832,843

Other

patents

Years Active: 2004-2025

Loading Chart...

Loading Chart...

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297203 - Pyrrolopyrimidine ITK inhibitors (2025-05-13),

2. 12281111 - Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same (2025-04-21),

3. 11820775 - Pyrrolopyrimidine ITK inhibitors (2023-11-21),

4. 11739086 - Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same (2023-08-29),

5. 11420966 - Substituted pyrrolopyridines as JAK inhibitors (2022-08-23),

6. 11021482 - Pyrrolopyrimidine ITK inhibitors (2021-06-01),

7. 10981906 - Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same (2021-04-20),

8. 10800775 - Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same (2020-10-13),

9. 10316038 - Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer (2019-06-11),

10. 10150783 - Heterocyclic ITK inhibitors for treating inflammation and cancer (2018-12-11),

11. 9884847 - Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof (2018-02-06),

12. 9771374 - Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof (2017-09-26),

13. 9708268 - ROR modulators and their uses (2017-07-18),

14. 9701663 - Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof (2017-07-11),

15. 9695200 - Heterocyclic ITK inhibitors for treating inflammation and cancer (2017-07-04),

As an expert on innovations, inventions, inventors, patent attorneys, assignees, and patents, I am here to provide you with information about inventor James Robert Blinn.

Title: The Innovative Mind of James Robert Blinn

Introduction:

James Robert Blinn is a prolific inventor based in O'Fallon, Missouri, United States, who has made significant contributions to the field of pharmaceuticals with a total of 19 patents to his name.

Latest Patents:

Among his latest patents are groundbreaking inventions in the field of medicine, particularly in the treatment of ITK-mediated diseases and the development of pyrrolopyridine JAK inhibitors for various conditions such as pruritus, alopecia, and psoriasis.

Career Highlights:

Throughout his career, James Robert Blinn has worked with esteemed companies such as Aclaris Therapeutics, Inc. and Innov17 LLC, where he has applied his expertise in pharmaceuticals to drive innovation and create impactful solutions for patients worldwide.

Collaborations:

James Robert Blinn has collaborated with notable individuals in the industry, including Eric Jon Jacobsen and Susan Landis Hockerman, to pioneer new treatments and therapies that address unmet medical needs and improve the quality of life for patients.

Conclusion:

In conclusion, James Robert Blinn's remarkable inventions and significant contributions to the field of pharmaceuticals underscore his dedication to advancing science and improving healthcare outcomes. His innovative spirit and collaborative efforts continue to inspire progress in the medical field, leaving a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…